Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

Publisher Correction: NCoR/SMRT co-repressors cooperate with c-MYC to create an epigenetic barrier to somatic cell reprogramming.

Zhuang Q, Li W, Benda C, Huang Z, Ahmed T, Liu P, Guo X, Ibañez DP, Luo Z, Zhang M, Abdul MM, Yang Z, Yang J, Huang Y, Zhang H, Huang D, Zhou J, Zhong X, Zhu X, Fu X, Fan W, Liu Y, Xu Y, Ward C, Khan MJ, Kanwal S, Mirza B, Tortorella MD, Tse HF, Chen J, Qin B, Bao X, Gao S, Hutchins AP, Esteban MA.

Nat Cell Biol. 2018 Jun 15. doi: 10.1038/s41556-018-0128-x. [Epub ahead of print]

PMID:
29907862
2.

NCoR/SMRT co-repressors cooperate with c-MYC to create an epigenetic barrier to somatic cell reprogramming.

Zhuang Q, Li W, Benda C, Huang Z, Ahmed T, Liu P, Guo X, Ibañez DP, Luo Z, Zhang M, Abdul MM, Yang Z, Yang J, Huang Y, Zhang H, Huang D, Zhou J, Zhong X, Zhu X, Fu X, Fan W, Liu Y, Xu Y, Ward C, Khan MJ, Kanwal S, Mirza B, Tortorella MD, Tse HF, Chen J, Qin B, Bao X, Gao S, Hutchins AP, Esteban MA.

Nat Cell Biol. 2018 Apr;20(4):400-412. doi: 10.1038/s41556-018-0047-x. Epub 2018 Mar 12. Erratum in: Nat Cell Biol. 2018 Jun 15;:.

PMID:
29531310
3.

Concurrent measurement of cerebral hemodynamics and electroencephalography during transcranial direct current stimulation.

Giovannella M, Ibañez D, Gregori-Pla C, Kacprzak M, Mitjà G, Ruffini G, Durduran T.

Neurophotonics. 2018 Jan;5(1):015001. doi: 10.1117/1.NPh.5.1.015001. Epub 2018 Jan 25.

PMID:
29392156
4.

[Cognitive impairment as a predictor of functional decline after hospitalization: DECOFIRH Study].

de Alboniga-Chindurza A, Anciones C, Acebron F, Ibanez D, Roiz-Rey P, Perez-Torre P, Garcia-Ribas G.

Rev Neurol. 2017 Nov 1;65(9):405-408. Spanish.

5.

Janus Electrochemistry: Asymmetric Functionalization in One Step.

Ibañez D, Valles E, Gomez E, Colina A, Heras A.

ACS Appl Mater Interfaces. 2017 Oct 11;9(40):35404-35410. doi: 10.1021/acsami.7b10073. Epub 2017 Sep 29.

PMID:
28925265
6.

Bipolar Spectroelectrochemistry.

Ibañez D, Heras A, Colina A.

Anal Chem. 2017 Apr 4;89(7):3879-3883. doi: 10.1021/acs.analchem.7b00856. Epub 2017 Mar 24.

PMID:
28290688
7.

Generation of Human Liver Chimeric Mice with Hepatocytes from Familial Hypercholesterolemia Induced Pluripotent Stem Cells.

Yang J, Wang Y, Zhou T, Wong LY, Tian XY, Hong X, Lai WH, Au KW, Wei R, Liu Y, Cheng LH, Liang G, Huang Z, Fan W, Zhao P, Wang X, Ibañez DP, Luo Z, Li Y, Zhong X, Chen S, Wang D, Li L, Lai L, Qin B, Bao X, Hutchins AP, Siu CW, Huang Y, Esteban MA, Tse HF.

Stem Cell Reports. 2017 Mar 14;8(3):605-618. doi: 10.1016/j.stemcr.2017.01.027. Epub 2017 Mar 2.

8.

In-situ Evidence of the Redox-State Dependence of Photoluminescence in Graphene Quantum Dots.

Barrera J, Ibañez D, Heras A, Ruiz V, Colina A.

J Phys Chem Lett. 2017 Jan 19;8(2):531-537. doi: 10.1021/acs.jpclett.6b02694. Epub 2017 Jan 11.

PMID:
28067529
9.

Simultaneous UV-Visible Absorption and Raman Spectroelectrochemistry.

Ibañez D, Garoz-Ruiz J, Heras A, Colina A.

Anal Chem. 2016 Aug 16;88(16):8210-7. doi: 10.1021/acs.analchem.6b02008. Epub 2016 Jul 28.

PMID:
27427898
10.

Arthroplasty of the distal ulna distal in managing patients with post-traumatic disorders of the distal radioulnar joint: measurement of quality of life.

Aita MA, Ibanez DS, Saheb GC, Alves RS.

Rev Bras Ortop. 2015 Oct 23;50(6):666-72. doi: 10.1016/j.rboe.2015.09.008. eCollection 2015 Nov-Dec.

11.

Answer to Photo Quiz: Things are not always what they seem (other causes of hepato-splenic nodules).

Caballero R, Ibañez D, Yanguas N, Pérez MF, Aísa G.

Neth J Med. 2016 May;74(4):176. No abstract available.

12.

Things are not always what they seem (other causes of hepato-splenic nodules).

Caballero R, Ibañez D, Yanguas N, Pérez MF, Aísa G.

Neth J Med. 2016 May;74(4):175. No abstract available.

13.

Robust fitting of Zernike polynomials to noisy point clouds defined over connected domains of arbitrary shape.

Ibañez DR, Gómez-Pedrero JA, Alonso J, Quiroga JA.

Opt Express. 2016 Mar 21;24(6):5918-33. doi: 10.1364/OE.24.005918.

PMID:
27136788
14.

Modified Framingham Risk Factor Score for Systemic Lupus Erythematosus.

Urowitz MB, Ibañez D, Su J, Gladman DD.

J Rheumatol. 2016 May;43(5):875-9. doi: 10.3899/jrheum.150983. Epub 2016 Feb 15.

PMID:
26879352
15.

Lack of Interferon and Proinflammatory Cyto/chemokines in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus.

Steiman AJ, Gladman DD, Ibañez D, Noamani B, Landolt-Marticorena C, Urowitz MB, Wither JE.

J Rheumatol. 2015 Dec;42(12):2318-26. doi: 10.3899/jrheum.150040. Epub 2015 Nov 15.

PMID:
26568589
16.

Experimental trial on surgical treatment for transverse fractures of the proximal phalanx: technique using intramedullary conical compression screw versus lateral compression plate.

Ibanez DS, Rodrigues FL, Salviani RS, Roberto FA, Pengo Junior JR, Aita MA.

Rev Bras Ortop. 2015 Aug 1;50(5):509-14. doi: 10.1016/j.rboe.2014.12.009. eCollection 2015 Sep-Oct.

17.

SLEDAI-2K Does Not Conceal Worsening in a Particular System When There Is Overall Improvement.

Touma Z, Gladman DD, Su J, Ibañez D, Urowitz MB.

J Rheumatol. 2015 Aug;42(8):1401-5. doi: 10.3899/jrheum.141088. Epub 2015 Jun 15.

PMID:
26077403
18.

Anti-dsDNA and Antichromatin Antibody Isotypes in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus.

Steiman AJ, Urowitz MB, Ibañez D, Li TT, Gladman DD, Wither J.

J Rheumatol. 2015 May;42(5):810-6. doi: 10.3899/jrheum.140796. Epub 2015 Mar 1.

PMID:
25729033
19.

Rapid spread of Clostridium difficile NAP1/027/ST1 in Chile confirms the emergence of the epidemic strain in Latin America.

Aguayo C, Flores R, Lévesque S, Araya P, Ulloa S, Lagos J, Hormazabal JC, Tognarelli J, Ibáñez D, Pidal P, Duery O, Olivares B, Fernández J.

Epidemiol Infect. 2015 Oct;143(14):3069-73. doi: 10.1017/S0950268815000023. Epub 2015 Feb 17.

PMID:
25687254
20.

Isolated hematuria and sterile pyuria may indicate systemic lupus erythematosus activity.

Ding JY, Ibañez D, Gladman DD, Urowitz MB.

J Rheumatol. 2015 Mar;42(3):437-40. doi: 10.3899/jrheum.140415. Epub 2015 Jan 15.

PMID:
25593226
21.

Vascular- and pregnancy-related outcomes in patients with systemic lupus erythematosus with positive antiphospholipid profile and thrombocytopenia.

Haddad A, Gladman DD, Ibañez D, Urowitz MB.

Lupus. 2015 Jul;24(8):822-6. doi: 10.1177/0961203314565689. Epub 2014 Dec 26.

PMID:
25542904
22.

The INTERGROWTH-21st Project Neurodevelopment Package: a novel method for the multi-dimensional assessment of neurodevelopment in pre-school age children.

Fernandes M, Stein A, Newton CR, Cheikh-Ismail L, Kihara M, Wulff K, de León Quintana E, Aranzeta L, Soria-Frisch A, Acedo J, Ibanez D, Abubakar A, Giuliani F, Lewis T, Kennedy S, Villar J; International Fetal and Newborn Growth Consortium for the 21st Century (INTERGROWTH-21st).

PLoS One. 2014 Nov 25;9(11):e113360. doi: 10.1371/journal.pone.0113360. eCollection 2014.

23.

Prolonged clinical remission in patients with systemic lupus erythematosus.

Steiman AJ, Urowitz MB, Ibañez D, Papneja A, Gladman DD.

J Rheumatol. 2014 Sep;41(9):1808-16. doi: 10.3899/jrheum.131137. Epub 2014 Aug 1.

PMID:
25086082
24.

Solving the puzzle of Parkinson's disease using induced pluripotent stem cells.

Zhao P, Luo Z, Tian W, Yang J, Ibáñez DP, Huang Z, Tortorella MD, Esteban MA, Fan W.

Exp Biol Med (Maywood). 2014 Nov;239(11):1421-32. doi: 10.1177/1535370214538588. Epub 2014 Jun 17. Review.

PMID:
24939824
25.

The correlation between carotid artery atherosclerosis and clinical ischemic heart disease in lupus patients.

Eder L, Gladman DD, Ibañez D, Urowitz MB.

Lupus. 2014 Oct;23(11):1142-8. doi: 10.1177/0961203314537696. Epub 2014 May 29.

PMID:
24876099
26.

Switching treatment between mycophenolate mofetil and azathioprine in lupus patients: indications and outcomes.

Al Maimouni H, Gladman DD, Ibañez D, Urowitz MB.

Arthritis Care Res (Hoboken). 2014 Dec;66(12):1905-9. doi: 10.1002/acr.22364.

27.

American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort.

Urowitz MB, Gladman DD, Ibañez D, Sanchez-Guerrero J, Romero-Diaz J, Gordon C, Bae SC, Clarke AE, Bernatsky S, Fortin PR, Hanly JG, Isenberg D, Rahman A, Wallace DJ, Ginzler E, Petri M, Bruce IN, Merrill JT, Nived O, Sturfelt G, Dooley MA, Alarcón GS, Fessler B, Steinsson K, Ramsey-Goldman R, Zoma A, Khamashta M, Manzi S, van Vollenhoven R, Ramos-Casals M, Aranow C, Stoll T.

J Rheumatol. 2014 May;41(5):875-80. doi: 10.3899/jrheum.130704. Epub 2014 Apr 1.

PMID:
24692526
28.

Changes in quality of life in the first 5 years of disease in a multicenter cohort of patients with systemic lupus erythematosus.

Urowitz M, Gladman DD, Ibañez D, Sanchez-Guerrero J, Bae SC, Gordon C, Fortin PR, Clarke A, Bernatsky S, Hanly JG, Wallace DJ, Isenberg D, Rahman A, Merrill J, Ginzler E, Alarcón GS, Fessler B, Khamashta M, Steinsson K, Petri M, Dooley M, Bruce IN, Manzi S, Sturfelt G, Nived O, Ramsey-Goldman R, Zoma A, Maddison P, Kalunian K, van Vollenhoven R, Aranow C, Romero Diaz J, Stoll T.

Arthritis Care Res (Hoboken). 2014 Sep;66(9):1374-9. doi: 10.1002/acr.22299.

29.

Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment.

Touma Z, Urowitz MB, Ibañez D, Gladman DD.

J Rheumatol. 2014 Apr;41(4):688-97. doi: 10.3899/jrheum.130005. Epub 2014 Jan 15.

PMID:
24429170
30.

Assessment of coronary risk based on cumulative exposure to lipids in systemic lupus erythematosus.

Nikpour M, Gladman DD, Ibanez D, Harvey PJ, Urowitz MB.

J Rheumatol. 2013 Dec;40(12):2006-14. doi: 10.3899/jrheum.121273. Epub 2013 Oct 15.

PMID:
24128779
31.

Recommendations for frequency of visits to monitor systemic lupus erythematosus in asymptomatic patients: data from an observational cohort study.

Gladman DD, Ibañez D, Ruiz I, Urowitz MB.

J Rheumatol. 2013 May;40(5):630-3. doi: 10.3899/jrheum.121094. Epub 2013 Mar 1.

PMID:
23457385
32.

Comparison of three anti-dsDNA assays: performance and correlation with systemic lupus erythematosus disease activity.

Venner AA, Ibañez D, Gladman DD, Urowitz MB, MacKinnon A, Blasutig IM, Yip PM.

Clin Biochem. 2013 Mar;46(4-5):317-20. doi: 10.1016/j.clinbiochem.2012.12.004. Epub 2012 Dec 12.

PMID:
23246539
33.

[Multifocal osteonecrosis in long-term corticoid treatment secondary to panhypopituitarism: a case report].

Ibáñez D, Martín MD, Rubio RÁ, Muel C.

Endocrinol Nutr. 2013 Aug-Sep;60(7):416-8. doi: 10.1016/j.endonu.2012.07.011. Epub 2012 Oct 26. Spanish. No abstract available.

PMID:
23108054
34.

SLEDAI-2K Responder Index 50 captures 50% improvement in disease activity over 10 years.

Touma Z, Gladman DD, Ibañez D, Urowitz MB.

Lupus. 2012 Oct;21(12):1305-11. Epub 2012 Jul 16.

PMID:
22800940
35.

Systemic lupus erythematosus disease activity Index 2000 Responder Index 50: sensitivity to response at 6 and 12 months.

Touma Z, Urowitz MB, Taghavi-Zadeh S, Ibañez D, Gladman DD.

Rheumatology (Oxford). 2012 Oct;51(10):1814-9. Epub 2012 Jun 19.

PMID:
22718868
36.

High-sensitivity C-reactive protein as a marker of cardiovascular risk in systemic lupus erythematosus.

Nikpour M, Harvey PJ, Ibanez D, Gladman DD, Urowitz MB.

Arthritis Rheum. 2012 Sep;64(9):3052-3. doi: 10.1002/art.34541. No abstract available.

37.

Long-term outcome of early neuropsychiatric events due to active disease in systemic lupus erythematosus.

Wang M, Gladman DD, Ibañez D, Urowitz MB.

Arthritis Care Res (Hoboken). 2012 Jun;64(6):833-7. doi: 10.1002/acr.21624. Epub 2012 Jan 30.

38.

Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period.

Steiman AJ, Gladman DD, Ibañez D, Urowitz MB.

Arthritis Care Res (Hoboken). 2012 Apr;64(4):511-8. doi: 10.1002/acr.21568.

39.

Ability of non-fasting and fasting triglycerides to predict coronary artery disease in lupus patients.

Touma Z, Gladman DD, Ibañez D, Urowitz MB.

Rheumatology (Oxford). 2012 Mar;51(3):528-34. doi: 10.1093/rheumatology/ker339. Epub 2011 Nov 24.

PMID:
22120460
40.

Autoantibody response to adjuvant and nonadjuvant H1N1 vaccination in systemic lupus erythematosus.

Urowitz MB, Anton A, Ibanez D, Gladman DD.

Arthritis Care Res (Hoboken). 2011 Nov;63(11):1517-20. doi: 10.1002/acr.20599.

41.
42.

Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort.

Urowitz MB, Gladman DD, Ibañez D, Fortin PR, Bae SC, Gordon C, Clarke A, Bernatsky S, Hanly JG, Isenberg D, Rahman A, Sanchez-Guerrero J, Wallace DJ, Ginzler E, Alarcón GS, Merrill JT, Bruce IN, Sturfelt G, Nived O, Steinsson K, Khamashta M, Petri M, Manzi S, Ramsey-Goldman R, Dooley MA, van Vollenhoven RF, Ramos M, Stoll T, Zoma A, Kalunian K, Aranow C.

Arthritis Care Res (Hoboken). 2012 Jan;64(1):132-7. doi: 10.1002/acr.20648.

43.

Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 enhances the ability of SLE Responder Index to identify responders in clinical trials.

Touma Z, Gladman DD, Ibañez D, Taghavi-Zadeh S, Urowitz MB.

J Rheumatol. 2011 Nov;38(11):2395-9. doi: 10.3899/jrheum.110550. Epub 2011 Sep 1.

PMID:
21885488
44.

Is there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus?

Touma Z, Gladman DD, Ibañez D, Urowitz MB.

J Rheumatol. 2011 Sep;38(9):1898-905. doi: 10.3899/jrheum.110007. Epub 2011 Jul 1.

PMID:
21724700
45.

Systemic lupus erythematosus disease activity index 2000 responder index-50: a reliable index for measuring improvement in disease activity.

Touma Z, Urowitz MB, Fortin PR, Landolt C, Toloza SM, Riddell C, Chandran V, Eder L, Ghanem A, Ziouzina O, Taghavi-Zadeh S, Ibañez D, Gladman DD.

J Rheumatol. 2011 May;38(5):868-73. doi: 10.3899/jrheum.101080. Epub 2011 Feb 15.

PMID:
21324961
46.

SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation.

Touma Z, Urowitz MB, Ibañez D, Gladman DD.

Lupus. 2011 Jan;20(1):67-70. doi: 10.1177/0961203310385163.

PMID:
21233149
47.

Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50.

Touma Z, Gladman DD, Ibañez D, Urowitz MB.

J Rheumatol. 2011 Feb;38(2):275-84. doi: 10.3899/jrheum.100724. Epub 2010 Dec 1.

PMID:
21123323
48.

Relationship between cardiac symptoms, myocardial perfusion defects and coronary angiography findings in systemic lupus erythematosus.

Nikpour M, Urowitz MB, Ibañez D, Gladman DD.

Lupus. 2011 Mar;20(3):299-304. doi: 10.1177/0961203310381512. Epub 2010 Nov 15.

PMID:
21078763
49.

Optimal frequency of visits for patients with systemic lupus erythematosus to measure disease activity over time.

Ibañez D, Gladman DD, Touma Z, Nikpour M, Urowitz MB.

J Rheumatol. 2011 Jan;38(1):60-3. doi: 10.3899/jrheum.100575. Epub 2010 Nov 15.

PMID:
21078718
50.

Burden of autoantibodies and association with disease activity and damage in systemic lupus erythematosus.

Touma Z, Gladman DD, Tulloch-Reid D, Toloza SM, Ibañez D, Fortin PR, Urowitz MB.

Clin Exp Rheumatol. 2010 Jul-Aug;28(4):525-31. Epub 2010 Aug 30.

PMID:
20659409

Supplemental Content

Loading ...
Support Center